Experimental brain cancer therapy infused directly into tumors shows promise in early trial
Disease control
Completed
This early-phase study tested a new drug called D2C7-IT for people with recurrent malignant glioma, a serious brain cancer. The drug was delivered directly into the tumor through tiny tubes over 72 hours. The main goal was to find the safest dose and see if it could help control …
Phase: PHASE1 • Sponsor: Darell Bigner • Aim: Disease control
Last updated May 13, 2026 16:01 UTC